Stocklytics Platform
Asset logo for symbol RMD
ResMed
RMD70
$228.83arrow_drop_down0.63%-$1.45
High Quality
S&P500
Asset logo for symbol RMD
RMD70

$228.83

arrow_drop_down0.63%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

ResMed (RMD) Stocklytics Forecast

ResMed Inc (RMD) is a leading medical device company specializing in the treatment of sleep apnea and other respiratory disorders. The company's stock price has been steadily increasing over the past few years, and many analysts believe that this trend will continue in the future. According to AI price prediction models and machine learning algorithms, ResMed Inc's stock price is expected to experience positive growth over the next few years. These models take into account various factors such as historical data, market trends, and industry performance to generate accurate forecasts.
Based on these predictions, ResMed Inc's stock price forecast for 2023 looks promising. Analysts have also set a price target for the company's stock, indicating their expectation of where the stock price will reach in the future. The average price target for ResMed Inc is expected to be higher than the current stock price, suggesting that it may be a good buy for investors. However, it is important to note that these price targets are based on analysts' opinions and should be taken with a grain of salt.
add ResMed  to watchlist

Keep an eye on ResMed

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for ResMed (RMD) stock?

Analysts have set a target price of $225.17 for ResMed (RMD), based on forecasts from 29 analysts. The predicted price range extends from a high of $290 to a low of $160. This represents a potential increase of up to 26.73% and a decrease of -30.08% from the current price of $228.83. These forecasts are as of 2022 Oct 20.
help

What are the analyst ratings for ResMed (RMD) stock?

The analyst ratings for ResMed (RMD) are distributed as follows: 8 analysts recommend buying, 7 have a neutral stance, and 1 suggest selling. The prevailing sentiment among the total of 16 analysts leans towards a buy rating. These ratings indicate the general sentiment among the analysts covering ResMed .
help

What is the AI price prediction for ResMed (RMD) stock?

At present, there is no AI or machine-learning-based price prediction available for ResMed (RMD) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level